Navigation Links
Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
Date:12/16/2008

DURHAM, N.C., Dec. 16 /PRNewswire/ -- Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body's mucosal defenses, today announced that the National Institutes of Health (NIH) have awarded the company a biodefense grant in excess of $850,000.

The purpose of the grant is to advance the development of safe and effective medical treatments that mitigate pulmonary injury arising from inhalation of radioactive particles using Parion's Radiation and Bioterrorism Countermeasures Platform. Parion will utilize the funding in a series of studies to evaluate the benefits of their lead compound, CF-552, combined with hypertonic saline, to increase removal of inhaled radioactive particles from the lungs. In previous clinical studies, treatment with CF-552 increased clearance of non-hazardous, radio-labeled particles from the lungs of healthy volunteers, as compared to vehicle alone. A portion of the research will be conducted by the Lovelace Respiratory Research Institute (LRRI), a not-for-profit research institute located in Albuquerque, New Mexico.

"This award represents an important step to help us demonstrate the capacity of our novel ENaC inhibitor technology to treat radiation and bio-terror threats," said Paul Boucher, Senior Director, Finance and Business at Parion. "We look forward to demonstrating the utility of our compound to provide a novel medical countermeasure for the prevention of radiation-induced lung injury following a nuclear incident."

ENaC inhibitors are therapeutic agents that maintain and stimulate hydration on the body's mucosal surfaces, including those on the lung, mouth, nose, eye and gastrointestinal tract. Maintaining the hydration of mucosal airway surfaces addresses the fundamental problem that produces infections in both acquired and genetic forms of chronic lung disease, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

The studies will be supported by Grant Number RC1-AI-081297, funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA). The award was made using authorities granted to the NIH by the Project BioShield Act of 2004. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, BARDA, or the NIH.

About Parion Sciences

Based in Durham, NC, Parion Sciences is a privately-held, development-stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. Parion's lead product candidate, CF-552, is currently in Phase II clinical development for the treatment dry mouth associated with Sjogren's syndrome. The company is also collaborating with Gilead Sciences on the development of drug candidates for pulmonary diseases. For more information, please visit www.parion.com.

About Lovelace Respiratory Research Institute

Lovelace Respiratory Research Institute is a not-for-profit research institution founded in 1947 by Dr. William Randolph Lovelace II. It is one of the nation's largest independent research institutions and the only one focused solely on respiratory health. Scientists at LRRI are committed to eradicating respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents, and developing more effective treatments. For more information see www.lrri.org.


'/>"/>
SOURCE Parion Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
2. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
3. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
4. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
5. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
8. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
9. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
10. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
11. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... cuvette manufacturers is their supercharged customer service and their extensive database of glass cuvette ... of inside information, they have recently revamped their manufacturing techniques to reduce lead times ...
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... ON (PRWEB) , ... February 03, 2016 , ... ... and validating a series of potential targets (epitopes) specific to misfolded, propagating strains ... targets to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from ...
Breaking Biology Technology:
(Date:2/3/2016)... Sweden , February 4, 2016 --> ... amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter ... profit amounted to SEK 517.6 M (loss: 30.0). Earnings per ... operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
Breaking Biology News(10 mins):